EP0000151B1 - 1-Substituierte Aminoindoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen - Google Patents

1-Substituierte Aminoindoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen Download PDF

Info

Publication number
EP0000151B1
EP0000151B1 EP78100166A EP78100166A EP0000151B1 EP 0000151 B1 EP0000151 B1 EP 0000151B1 EP 78100166 A EP78100166 A EP 78100166A EP 78100166 A EP78100166 A EP 78100166A EP 0000151 B1 EP0000151 B1 EP 0000151B1
Authority
EP
European Patent Office
Prior art keywords
hydrogen
compound
formula
carbon atoms
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP78100166A
Other languages
English (en)
French (fr)
Other versions
EP0000151A1 (de
Inventor
Gerhard Dr. Bormann
Richard Dr. Berthold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of EP0000151A1 publication Critical patent/EP0000151A1/de
Application granted granted Critical
Publication of EP0000151B1 publication Critical patent/EP0000151B1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to 1-substituted aminoindoline derivatives.
  • Alkyl, alkoxy and alkylthio preferably contain 1 or 2, especially 1 carbon atom.
  • Halogen is preferably chlorine.
  • a compound of formula I may be obtained by a process comprising cyclizing a compound of formula II, wherein
  • the process according to the invention may be effected in a manner analogous to known methods for cyclizing analogous amino derivatives.
  • X is e. g. a group -NHR a , wherein R a is alkyl of 1 to 4 carbon atoms, especially methyl, or R a is hydrogen.
  • the reaction is preferably effected in an inert solvent such as methanol or ethanol, or, when the amine of formula IV (see below) is liquid at the reaction temperature, the reaction is conveniently effected in the absence of any additional solvent.
  • the reaction is preferably effected in the presence of a mineral acid such as hydrochloric or hydroiodic acid.
  • the reaction temperature may be from room temperature to about 150°C and is preferably at least 50° C, e. g. the boiling temperature of the reaction mixture.
  • the compounds of formula I may be isolated and purified in accordance with known methods.
  • the compounds of formula I may be present in free form, or in the form of acid addition salts.
  • Acid addition salt forms for example, the hydrochloride or hydrogen maleate, may be produced from the free form in known manner, and vice-versa.
  • the compounds of formula I may also be present in tautomeric form, i. e. with the double bond adjacent to one of the other two nitrogen atoms of the guanidine moiety, insofar as this nitrogen atom is not substituted by an alkyl group R i or R 2 . It is to be appreciated that such tautomeric forms also fall under the scope of formula I.
  • the production of the starting materials may be effected in known manner.
  • a compound of formula II may e. g. be produced by reacting a compound of formula III, wherein R 3 to R 5 and X are as defined above and the group -S-Y is a leaving group, with a compound of formula IV, wherein R i , R 2 and n are as defined above.
  • Y may e. g. be alkyl of 1 to 4 carbon atoms, preferably methyl.
  • the reaction conditions may be chosen such as to be identical with the conditions for cyclization according to the invention.
  • the compounds of formula III are then advantageously reacted with the compounds of formula IV to give directly the corresponding compounds of formula I, without intermediate isolation of the compounds offormula II.
  • the starting material is obtained as follows:
  • the compounds of formula I exhibit pharmacological activity.
  • the compounds possess vasoconstricting activity, as indicated by standard tests.
  • this activity may be observed in vivo in rats treated in accordance with the principles of J. S. Gillespie and T. C. Muir, Br. J. Pharmac. Chemother. (1967) 30, 78-87): a pressor effect is elicited following i. v. administration of from about 0.02 to about 50 ⁇ g/kg, particularly of from about 0.02 to about 0.5 ⁇ g/kg of the compounds.
  • the compounds are therefore indicated for use as vasoconstricting agents, e. g. for the prophylaxis and treatment of vascular headaches such as migraine, and of orthostatic disorders such as orthostatic hypotension and its symptoms, such as vertigo.
  • an indicated daily dose is from about 0.0025 to about 1 mg, conveniently administered in divided doses 2 to 4 times a day in unit dosage form containing from about 0.0005 to about 0.5 mg, or in sustained release form.
  • the activity of the compound of Example 1 is especially interesting.
  • the compounds of formula I may be administered in free form or in pharmaceutically acceptable acid addition salt form. Such forms exhibit the same order of activity as the free form.
  • the present invention also provides a pharmaceutical composition comprising a compound of formula I, in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutical carrier or diluent. Such compositions may be in the form of, for example, a solution or a tablet.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (11)

1. Ein Verfahren zur Herstellung einer Verbindung der Formel I,
Figure imgb0008
worin
eines von R1 und R2 Wasserstoff und das andere Wasserstoff oder Alkyl mit 1 -4 Kohlenstoffatomen bedeutet,
R3 Wasserstoff oder in 2- oder 3-Stellung ständiges Alkyl mit 1-4 Kohlenstoffatomen bedeutet,
R4 und R5 unabhängig voneinander für Wasserstoff, Alkyl mit 1-4 Kohlenstoffatomen, Alkoxy mit 1-4 Kohlenstoffatomen, Alkylthio mit 1-4 Kohlenstoffatomen oder Halogen mit einer Ordnungszahl von 9 bis 35 stehen, und
n für die Zahl 2, 3 oder 4 steht,

oder einer ihrer tautomeren Formen, beinhaltend die Cyclisierung einer Verbindung der Formel II,
Figure imgb0009
worin
R1 bis R5 und n obige Bedeutung besitzen und
X für eine Abgangsgruppe steht.
2. Eine Verbindung der Formel wie in Anspruch 1 definiert, oder eine ihrer tautomeren Formen.
3. Eine wie in Anspruch 2 definierte Verbindung, in der R1 bis R5 Wasserstoff bedeuten und n für die Zahl 2 steht.
4. Eine wie in Anspruch 2 definierte Verbindung, in der Ri, R2 und R5 Wasserstoff bedeuten und n für die Zahl 2 steht.
5. Eine wie in Anspruch 4 definierte Verbindung, in der R3 Wasserstoff bedeutet und R4 für 5-Chlor steht, oder R3 2-Methyl bedeutet und R4 für Wasserstoff steht.
6. Eine wie in Anspruch 4 definierte Verbindung, in der R3 3-Methyl bedeutet und R4 für Wasserstoff steht, oder R3 Wasserstoff bedeutet und R4 für 4-Methyl steht.
7. Eine wie in Anspruch 4 definierte Verbindung, in der R3 Wasserstoff bedeutet und R4 für 4-Methoxy steht, oder R3 Wasserstoff bedeutet und R4 für 7-Methyl steht.
8. Eine Verbindung, wie in irgendeinem der Ansprüche 2 bis 7 definiert, in freier Form.
9. Eine Verbindung, wie in irgendeinem der Ansprüche 2 bis 7 definiert, in Säureadditionssalzform.
10. Eine pharmazeutische Zusammensetzung, enthaltend eine Verbindung, wie in irgendeinem der Ansprüche 2 bis 7 definiert, in freier Form oder in physiologisch verträglicher Säureadditionssalzform, zusammen mit einem Träger- bzw. Verdünnungsmittel.
11. Eine Verbindung, wie in Anspruch 2 definiert, zur Anwendung in einem Verfahren zur therapeutischen Behandlung des menschlichen oder tierischen Körpers.
EP78100166A 1977-06-28 1978-06-15 1-Substituierte Aminoindoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen Expired EP0000151B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH7915/77 1977-06-28
CH791577 1977-06-28

Publications (2)

Publication Number Publication Date
EP0000151A1 EP0000151A1 (de) 1979-01-10
EP0000151B1 true EP0000151B1 (de) 1981-05-20

Family

ID=4332315

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78100166A Expired EP0000151B1 (de) 1977-06-28 1978-06-15 1-Substituierte Aminoindoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Country Status (13)

Country Link
EP (1) EP0000151B1 (de)
JP (1) JPS5412373A (de)
AU (1) AU3746878A (de)
CA (1) CA1094553A (de)
DE (1) DE2860709D1 (de)
DK (1) DK275278A (de)
ES (1) ES471125A1 (de)
FI (1) FI781947A7 (de)
IL (1) IL55005A (de)
IT (1) IT7850073A0 (de)
NZ (1) NZ187675A (de)
PT (1) PT68217A (de)
ZA (1) ZA783708B (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444035A1 (fr) * 1978-12-13 1980-07-11 Sandoz Sa Nouvelles 1-amino-indolines, leur preparation et leur application comme medicaments
EP0072954A3 (en) * 1981-08-22 1983-09-28 Beiersdorf Aktiengesellschaft Isoindolin-2-yl-amino-imidazolines and isoindolin-2-yl guanidines, process for their preparation and their use as medicines
EP0146787A3 (en) * 1983-12-03 1985-11-21 Dr. Karl Thomae Gmbh Indole derivatives, medicaments containing these compounds, and process for their preparation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH529702A (de) * 1970-07-06 1972-10-31 Sandoz Ag Verfahren zur Herstellung neuer Benz(cd)indole
GB1408362A (en) * 1973-05-25 1975-10-01 Lepetit Spa 2-pyrrol-1-yl amino 4,5-dihydro-1-h-imidazole derivatives

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444035A1 (fr) * 1978-12-13 1980-07-11 Sandoz Sa Nouvelles 1-amino-indolines, leur preparation et leur application comme medicaments
EP0072954A3 (en) * 1981-08-22 1983-09-28 Beiersdorf Aktiengesellschaft Isoindolin-2-yl-amino-imidazolines and isoindolin-2-yl guanidines, process for their preparation and their use as medicines
US4526897A (en) * 1981-08-22 1985-07-02 Beiersdorf Aktiengesellschaft Hypertensive isoindolin-2-yl-aminoimidazolines and isoindolin-2-yl-guanidines
EP0146787A3 (en) * 1983-12-03 1985-11-21 Dr. Karl Thomae Gmbh Indole derivatives, medicaments containing these compounds, and process for their preparation

Also Published As

Publication number Publication date
CA1094553A (en) 1981-01-27
IL55005A0 (en) 1978-08-31
ES471125A1 (es) 1979-09-16
EP0000151A1 (de) 1979-01-10
NZ187675A (en) 1981-02-11
ZA783708B (en) 1980-02-27
IT7850073A0 (it) 1978-06-28
AU3746878A (en) 1980-01-03
PT68217A (fr) 1978-07-01
DE2860709D1 (en) 1981-08-27
IL55005A (en) 1981-12-31
FI781947A7 (fi) 1978-12-29
DK275278A (da) 1978-12-29
JPS5412373A (en) 1979-01-30

Similar Documents

Publication Publication Date Title
US4059621A (en) Substituted benzamido propanolamines
WO2003074525A1 (fr) Compose heterocyclique azote
CN101006090A (zh) 4[[(7r)－8－环戊基－7－乙基－5,6,7,8－四氢－5－甲基－4－6－氧代－2－哌啶基]氨基]－3－甲氧基－n－(1－甲基－4－哌啶基)－苯甲酰胺的水合物及多晶型物，其制造方法及其作为药物的用途
JPH0739387B2 (ja) 新規１−ベンジル−アミノアルキル−ピロリジノン化合物及びその製造方法
US4575508A (en) 2-Substituted 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-β-carbolines, and their use as antiarrhythmic agents
GB2243832A (en) 2-substituted 4-acetamido-5-chloro-n-[2-(diethylamino)ethyl]-benzamide derivative
US3579524A (en) 2-aminoalkyl derivatives of phthalimidines
US4379160A (en) Carbazole compounds and medicinal use thereof
EP0000151B1 (de) 1-Substituierte Aminoindoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
IE46907B1 (en) Pyridobenzodiazepines
US4001271A (en) 3-(isopropyl amino alkoxy)-2-phenyl-isoindolin-1-ones
CZ327494A3 (en) Esters of nicotinic acid and process for preparing thereof
US3530140A (en) Certain pyridyl-hydrazino-2-yl-imidazolines
US5472966A (en) Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
US3972994A (en) Disubstituted azabicycloalkanes
CZ280490A3 (en) Pyridobenzoindole derivatives, process of their preparation and a pharmaceutical containing thereof
HK24194A (en) Pyrrolo[1,2-a][4,1]benzoxazepines, process for their preparation, pharmaceutical compositions containing these compounds and therapeutical use
NZ201642A (en) 1-phenylindazol-3-one derivatives and pharmaceutical compositions
KR100917041B1 (ko) 5-ｈｔ7 수용체에 길항작용을 갖는 신규한 화합물
US3576811A (en) 1-alkyl-1-(beta-piperidino-ethyl)-1,2,3,4- tetrahydronaphthalen-2-ones
EP0338877A1 (de) Verbindungen zur selektiven Bindung von s-hydroxytryptamine 1-A-rezeptoren und sie enthaltenden Arzneimittelzusammensetzungen
EP0375536B1 (de) 1,7'-[Imidazo-[1,2-a]pyridin]5'-(6'H)one-Derivate und Verfahren zu deren Herstellung
US3635962A (en) 4 - bis-morpholino- and 2
HUT61760A (en) Process for producing bridged, bicyclic imides comprising 4-/4-(3-benzisothiazolyl)-1-piperazinyl/-butyl group and pharmaceutical compositions comprising such compounds
US3308133A (en) Novel alkylene diamine derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB LU NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE FR GB LU NL SE

Designated state(s): BE CH DE FR GB LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19810615

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19810619

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19810630

Ref country code: CH

Effective date: 19810630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19810630

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19810731

Year of fee payment: 4

REF Corresponds to:

Ref document number: 2860709

Country of ref document: DE

Date of ref document: 19810827

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19820616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19830101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19830201

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19830331

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881117

EUG Se: european patent has lapsed

Ref document number: 78100166.4

Effective date: 19850612

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT